INNATE PHARMA
Biotechnology · Healthcare
COO
2 appearances
Latest appearance 2026-09-17
Yanis Morel
COO
INNATE PHARMA
Equibles does not estimate personal net worth.
About Yanis Morel
Yanis Morel is recorded as COO at INNATE PHARMA. Yanis Morel has spoken on 2 earnings calls across 1 company, most recently for INNATE PHARMA on September 17, 2026. INNATE PHARMA is classified in the Biotechnology industry within the Healthcare sector.
Yanis Morel on recent calls
“As a reminder, under our Monalizumab partnership with AstraZeneca, we have received up to date 450 million. And the additional potential milestones in the agreement are up to 825 million, together with double-digit royalties outside Europe and 50% profit sharing in Europe.”
“IPH4502 is our novel and differentiated Nectin-4-Exatecan ADC, which is in Phase 1. Turning to slide 11, IPH4502 has been designed to overcome the limitation of the first-generation Nectin-4 ADCs and to deliver a more favorable therapeutic profile across multiple solid tumors.”
Affiliation history
-
INNATE PHARMA
COO
Transcript header (unverified)
Current
Company network
Recent activity
-
Earnings call
Publication of half year financial statements
INNATE PHARMA
-
Earnings call
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
INNATE PHARMA